Human Fibrinogen Market Competitive Analysis till 2028

Human Fibrinogen Market” Research Report Growth (2023-2028):

Fibrinogen (factor I) is a glycoprotein in vertebrates that helps in the formation of blood clots. Human Fibrinogen is used as a medicine for blood disease. Human Fibrinogen is a preparation of coagulation factors prepared from pooled plasma. Currently, only RiaSTAP (CSL Behring) is licensed in a number of countries for multiple indications including treating acute bleeding episodes with Hypofibrinogenemia. Other manufacturer’s products are justly used in local region or countries.
Market Analysis and Insights: Global Human Fibrinogen Market
Due to the COVID-19 pandemic, the global Human Fibrinogen market size is estimated to be worth USD 795.8 million in 2022 and is forecast to a readjusted size of USD 2207 million by 2028 with a CAGR of 15.5% during the forecast period 2023-2028.
Global Human Fibrinogen key players include CSL Behring, LFB Group, Shanghai RAAS Blood Products, Jiangxi Boya Bio-Pharmaceutical, GREEN CROSS, etc. Global top five manufacturers hold a share about 90%. Asia-Pacific is the largest consumption market, with a share about 60%, followed by Americas and Europe, total have a share over 30 percent. In terms of product, Human Fibrinogen Concentrate is the largest segment, with a share over 99%. And in terms of application, the largest application is Surgical Procedures.
Global Human Fibrinogen Scope and Market Size
The global Human Fibrinogen market is segmented by region (country), company, by Type and by Application. Players, stakeholders, and other participants in the global Human Fibrinogen market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2017-2028.

List of TOP KEY PLAYERS in Human Fibrinogen Market Report are –

Related Articles

Back to top button